Skip to main content
close menu
close menu

Search UK HealthCare

Jill Kolesar, PharmD

Director, Early Phase Clinical Trials Center
Co-Director, Molecular Tumor Board
Why are there no ratings?
jill-kolesar
  • About

    Faculty Rank

    Professor

    Degree

    Master of Science University of Wisconsin School of Medicine and Public Health

    PharmD Univ Of Texas At San Antonio

    Bachelor of Science Pharmacy University of Wisconsin

    Certifications and Special Training

    Mini-Sabbatical University of Minnesota-Twin Cities

    Fellowship

    Fellowship The University of Texas Science Center

    Residency

    Residency Medical Center Hospital

Are you happy with the care you received from this provider?

Please let us know by filling out a patient satisfaction survey when you get one. You can also leave an online review by clicking the button below.

Leave a review
  • Publications

    Publications

    1. Defective DNA repair in hereditary ovarian cancers: Implications for therapy. Kolesar Jill, Burgess Brian. (2018). American Journal of Health System Pharmacy, 75(21), 1697-1707.
    2. Pharmacodynamic study using FLT PET/CT in advanced solid malignancies treated with a sequential combination of X-82 and docetaxel. Scarpelli M, Rampurwala M, Eickhoff J, Carmichael L, Heideman J, Binger K, Kolesar Jill, Perlman S, Harrow K, Dukart G, Liang C, Jeraj R, Liu G, JY Bruce. (2018). Cancer Chemotherapy and Pharmacology, 82(2), 211-19.
    3. Smoking, Sex, and Non-Small Cell Lung Cancer: Steroid Hormone Receptors in Tumor Tissue (S0424). Cheng T D, Darke A K, Redman M W, Zirpoli G R, Davis W, Payne Ondracek R, Bshara W, Omilian A R, Kratzke R, Reid M E, Molina Chen Y, Kolesar Jill, MacRae R M, Moon J, Mack P, Gandara D R, Kelly K, Santella R M, Albain K S, Ambrosone C B. (2018). Journal of the National Cancer Institute, 110(7), 734-42.
    4. Low-Fat Abiraterone Food Effect Is of Little Consequence. Kolesar Jill, Liu Glenn. (2018). Journal of Clinical Oncology, 36(14), 1385-86.
    5. Phenome-Wide Association Studies (PheWASs) Offer New Opportunities for Drug Repositioning. Rastegar-Mojarad M, Ye J, Kolesar JM, Lin SM and Hebbring SJ. Nat Biotechnol. Apr 7;33:342-5, 2015.
    6. Detection of a point mutation in NQO1 (DT diaphorase) in a patient with colon cancer. Kolesar JM, Burris H, Kuhn JG. J Natl Cancer Inst 87:1022 24, 1995.
    7. Implementation and clinical utility of an integrated academic-community regional molecular tumor board. Burkard ME, Deming D, Parsons K, Schuh M, Leal T, Uboha N, Lang J. Thompson M, Warren R, Bauman J, Mably M, Laffin J, Paschal C, Lager A, Lee K, Matkowskyj K, Buehler D, Rehrauer W, Kolesar J. JCO Precision Oncology, in press.
    8. A pilot, first-in-human, pharmacokinetic study of 9cUAB30 in healthy volunteers. Kolesar JM, Hoel R, Pomplun M, Havighurst T, Stublaski J, Wollmer B, Krontiras H, Brouillette W, Muccio D, Kim K, Grubbs CJ, Bailey HE. Cancer Prev Res 3:1565-1570, 2010. PMCID: PMC3204611
    9. Prioritization of family member sequencing for the detection of rare variants. Sippy R, Kolesar JM, Darst BF, Engelman CD. BMC Proceedings 2016; 10 (S7):11.
  • Research

    Cancer Center Member

    Research Focus

    Dr. Kolesar’s research focuses on the drug development of anticancer agents with an emphasis on targeted therapies and biomarkers. She has authored more than 200 abstracts, research articles, and book chapters, and as a principal investigator she has received more than $1.5 million in research funding from the NCI, American Cancer Society and other sources. Jill has received teaching and research awards from local, national and international organizations including the Innovations in Teaching Award from the American Association of Colleges of Pharmacy.

    For Referring Physicians

    567 Todd Building - BioPharm Complex
    789 South Limestone
    Lexington, KY 40536
    United States

    Phone
    859-323-4978